文献速递瓣膜病与结构性心脏病冠心病

低危患者TAVR与SAVR远期结局更新荟萃分析

Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

该系统综述与荟萃分析纳入6项随机对照试验共5341例低危重度主动脉瓣狭窄患者,比较TAVR与SAVR的远期结局。基于重建时间事件个体参与者数据的汇总生存分析显示,5年时TAVR的全因死亡风险降低20%(HR 0.80),死亡或致残性卒中复合风险降低19%(HR 0.81),卒中风险无差异(HR 0.97)。

要点

  • 低危患者TAVR术后5年全因死亡风险低于SAVR(HR 0.80)
  • TAVR组死亡或致残性卒中复合风险较SAVR降低19%
  • 两组卒中风险无显著差异(HR 0.97)

核心结论

  • 在低危重度主动脉瓣狭窄患者中,TAVR较SAVR与全因死亡及死亡或致残性卒中风险降低相关,卒中发生率相当。

研究设计与样本

  • 更新系统综述,纳入6项随机对照试验,共5341例低危患者,TAVR组2717例、SAVR组2624例,加权平均随访35.7个月。
  • 采用重建时间事件个体参与者数据进行传统配对荟萃分析与汇总生存分析,拟合Cox比例风险脆弱模型及限制性平均生存时间模型。

主要发现

  • 5年汇总生存分析显示,TAVR组全因死亡风险较SAVR降低20%(HR 0.80;95%CI 0.66-0.97;P=0.02)。
  • TAVR组全因死亡或致残性卒中复合风险较SAVR降低19%(HR 0.81;95%CI 0.68-0.96;P=0.01)。
  • 卒中风险两组无差异(HR 0.97;95%CI 0.74-1.26;P=0.80)。

临床怎么用

  • 对于低危重度主动脉瓣狭窄患者,TAVR可作为SAVR的合理替代方案,尤其在全因死亡和致残性卒中复合终点方面。
  • 临床决策仍需结合患者年龄、解剖特征及长期随访数据个体化评估,年轻患者尤需谨慎。

局限性

  • 多数患者尚未完成5年随访,随着更长期数据积累,当前结论可能发生变化。
  • 需要进一步随机试验和更长期随访,尤其在年轻患者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Longer-term outcomes are especially important for lower-risk patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Additional randomized data comparing TAVR and SAVR have recently become available. OBJECTIVES: The purpose of this study was to perform an updated systematic review with conventional pairwise meta-analyses and pooled survival analyses using reconstructed time-to-event individual participant data (IPD) including the totality of randomized evidence comparing longer-term clinical outcomes after TAVR and SAVR in lower-risk patients. METHODS: The prespecified primary endpoint was all-cause death. Key secondary endpoints included stroke and the composite of death or disabling stroke. Cox proportional hazards frailty regression and restricted mean survival time models were fitted using reconstructed time-to-event IPD. In sensitivity analyses, proportional odds models were fitted with frailty terms. Conventional pairwise meta-analyses were performed under random and fixed effects assumptions. RESULTS: Six trials enrolling 5,341 lower-risk patients were included with 2,717 randomized to TAVR and 2,624 randomized to SAVR (weighted mean follow-up of 35.7 months). At 5 years in the pooled survival analyses of reconstructed time-to-event IPD, TAVR was associated with a 20% reduction in the hazard of all-cause death (HR: 0.80; 95% CI: 0.66-0.97; P = 0.02) and a 19% reduction in the hazard of all-cause death or disabling stroke (HR: 0.81; 95% CI: 0.68-0.96; P = 0.01) compared with SAVR. There was no difference in stroke (HR: 0.97; 95% CI: 0.74-1.26; P = 0.80). CONCLUSIONS: In lower-risk patients, TAVR was associated with a reduced hazard of death and death or disabling stroke compared with SAVR, while rates of stroke were equivalent. Most patients have not yet undergone 5-year follow-up, and so these findings may change as further longer-term data become available. The present data are informative for lower-risk patients and treating clinicians, but further randomized trials and longer-term follow-up are required, particularly in younger patients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Reddy RK, Howard JP, Mack MJ, et al. Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol. 2025. PMID: 40044297. doi:10.1016/j.jacc.2024.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。